Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIBROSARC: Onfekafusp alfa + Doxorubicin in Advanced Soft Tissue Sarcoma
NCT04650984Phase 3Recruiting
- Sponsor
- Philogen
- Start
- Nov 2017
- Primary completion
- Dec 2025
- Modality
- Antibody Fragments, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of onfekafusp alfa in soft tissue sarcoma (STS) (2 arms), sponsored by Philogen. Primary endpoint: Median Progression Free Survival. Started Nov 2017; status: recruiting.
02
Drugs
onfekafusp alfa
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04650984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04650984.